Study of hereditary angioedema diagnosis and care in Egypt
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study is looking at how hereditary angioedema (a rare cause of severe swelling) is diagnosed and managed in Egypt. It is an observational study, meaning you won't receive any study medicine—just regular medical care while researchers collect information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hereditary angioedema caused by low or abnormal C1 inhibitor protein (Type 1 or Type 2).
- Your diagnosis and/or treatment must have occurred between January 2015 and August 2025.
- If you join the forward-looking part of the study, you will need to have at least one visit with the study doctor.
- You must not have another cause of swelling, such as acquired angioedema, drug-induced angioedema, allergic reactions, or other types.
- If joining the forward-looking part, you were not part of the earlier (retrospective) phase of this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study looks at whether people with hereditary angioedema (a rare condition causing sudden swelling) experience thoughts of suicide. The goal is to understand the emotional impact of living with this condition and find ways to support patients better.
This study looks at how well Takhzyro (lanadelumab) works for people with a specific type of hereditary angioedema (HAE) that is caused by a C1 inhibitor deficiency. It is for teenagers and adults who have already been taking Takhzyro for at least 6 months.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This trial lets children who already took part in a previous CSL312 study for hereditary angioedema continue receiving the medicine. It helps ensure they don't have a gap in treatment while longer-term safety and effects are monitored.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.